FAQ

TGN-1412 monoclonal antibody

Known as: TGN 1412, monoclonal antibody TGN1412, TAB08 
 

Topic mentions per year

Topic mentions per year

2006-2016
05101520062016

Related topics

Related topics

1 relation

Broader (1)

Antibodies, Monoclonal, Humanized

Related mentions per year

Related mentions per year

1990-2018
1990200020102020
TGN-1412 monoclonal antibody
Antibodies, Monoclonal, Humanized

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
The storm has cleared: lessons from the CD28 superagonist TGN1412 trial
The life-threatening cytokine-release syndrome suffered by six volunteers in a Phase I clinical trial following administration of… (More)
Is this relevant?
2011
2011
Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412.
Human volunteers receiving TGN1412, a humanized CD28-specific monoclonal antibody, experienced a life-threatening cytokine… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells.
BACKGROUND AND PURPOSE In 2006, a life-threatening 'cytokine storm', not predicted by pre-clinical safety testing, rapidly… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2010
2010
Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412.
TGN1412 is a "superagonistic" CD28 monoclonal antibody (IgG4) that caused serious adverse events at its first time in human… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo
Two humanized IgG4 antibodies, natalizumab and gemtuzumab, are approved for human use, and several others, like TGN1412, are or… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2008
2008
Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies
Superagonistic CD28 antibodies (CD28SAs) activate T lymphocytes without concomitant perturbation of the TCR/CD3-complex. In… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2008
2008
CD28 superagonists: what makes the difference in humans?
In 2006, a clinical trial with the CD28 superagonistic antibody TGN1412 in London turned into a catastrophe. Studies are… (More)
  • table 1
Is this relevant?
2008
2008
A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats.
Administration of the CD28 superagonistic antibody JJ316 is an efficient means to treat autoimmune diseases in rats, but the… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
"Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics.
The CD28-specific mAb TGN1412 rapidly caused a life-threatening "cytokine storm" in all six healthy volunteers in the Phase I… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.
Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?